Overdose of Glucose 5% Labesfal 20% may lead to hyperglycaemia and glycosuria leading to dehydration, hyperosmolar coma and death.
The blood levels of Glucose 5% Labesfal can be reduced by slow infusion of insulin. Careful monitoring of blood Glucose 5% Labesfal levels would be necessary.
Glucose 5% Labesfal 20% is contraindicated in patients with:
-
- the Glucose 5% Labesfal - galactose malabsorption syndrome
- anuria or intraspinal or intracranial haemorrhage, or ischaemic stroke and in patients with delirium tremens if such patients are already dehydrated
- with hyperglycaemic coma.
Glucose 5% Labesfal solutions which do not contain electrolytes, should not be administered concomitantly with blood through the same infusion set, because of the possibilities of agglomeration.
| Very common (> 1/10); Common (> 1/100 to < 1/10); Uncommon (> 1/1,000 to < 1/100); Rare (> 1/10,000 to < 1/1,000); Very rare (<1/10,000), Not known (cannot be estimated from the available data) | ||
| System Organ Class (SOC) | Adverse reaction (MedDRA term) | Frequency |
| Metabolism and nutrition disorders | Hospital acquired hyponatraemia * Hyperglycaemia** Hypokalaemia Hypophosphataemia Hypomagnesaemia Fluid and electrolyte imbalance. | Not known |
| Nervous system disorders | Hyponatraemic encephalopathy* | Not known |
| General disorders and administration site conditions | Pain at the injection site Vein irritation Venous thrombosis Phlebitis | Not known |
* Hospital acquired hyponatraemia may cause irreversible brain injury and death due to development of acute hyponatraemic encephalopathy.
** Hyperglycaemia (possibly indicated by mental confusion or loss of consciousness) and glycosuria may occur as a result of the rate of administration or metabolic insufficiency. If undetected and untreated hyperglycaemia can lead to dehydration, hyperosmolar coma and death.
The administration of Glucose 5% Labesfal without adequate levels of thiamine may precipitate overt deficiency states e.g. Wernicke's encephalopathy. Sodium retention, oedema, pulmonary oedema and congestive heart failure may be induced in patients with severe under-nutrition.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
No further information other than that which is included in the Summary of Product Characteristics.
Glucose 5% Labesfal 20% is hypertonic (in vitro tonicity, in a container) and provides a source of calories in a minimal volume of water. Glucose 5% Labesfal 20% is frequently used in both adults and children to restore blood Glucose 5% Labesfal concentrations in the treatment of hypoglycaemia resulting from insulin excess or from other causes.
Glucose 5% Labesfal 20% may be used to provide temporary relief from the symptoms of cerebral oedema and from hypoglycaemic coma. Hyperosmotic Glucose 5% Labesfal with or without insulin may also correct hyperkalaemia in renal failure.
Pharmacotherapeutic group: Solutions for parenteral nutrition, Carbohydrates
ATC code: B05BA03
The metabolism of Glucose 5% Labesfal is an energy source for the body.
Glucose 5% Labesfal is rapidly metabolised into carbon dioxide and water
Rapid administration of hypertonic Glucose 5% Labesfal solutions may produce substantial hyperglycaemia and hyperosmolar syndrome; patients should be observed for signs of mental confusion and loss of consciousness, especially those patients with chronic uraemia or carbohydrate intolerance.
Prolonged use in parenteral nutrition may affect insulin production; blood and urine Glucose 5% Labesfal should be monitored.
Glucose 5% Labesfal 20 % intravenous infusion is a hypertonic solution (in vitro, in a container). In the body, however, Glucose 5% Labesfal containing fluids can become extremely physiologically hypotonic due to rapid Glucose 5% Labesfal metabolism.
Depending on the tonicity of the solution, the volume and rate of infusion and depending on a patient's underlying clinical condition and capability to metabolize Glucose 5% Labesfal, intravenous administration of Glucose 5% Labesfal can cause electrolyte disturbances most importantly hypo- or hyperosmotic hyponatraemia.
Hyponatraemia:
Patients with non-osmotic vasopressin release (e.g. in acute illness, pain, post-operative stress, infections, burns, and CNS disease), patients with heart, liver and kidney diseases and patients exposed to vasopressin agonists are at risk of acute hyponatraemia upon infusion of hypotonic fluids.
Acute hyponatraemia can lead to acute hyponatraemic encephalopathy (brain oedema) characterized by headache, nausea, seizures, lethargy and vomiting. Patients with brain oedema are at particular risk of severe, irreversible and life-threatening brain injury.
Children, women in the fertile age and patients with reduced cerebral compliance (e.g. meningitis, intracranial bleeding, and cerebral contusion) are at particular risk of the severe and life-threatening brain swelling caused by acute hyponatraemia.
Intravenous administration of Glucose 5% Labesfal 20% may result in other electrolyte disturbances such as: hypokalaemia, hypophosphataemia and hypomagnesaemia.
Special care should be taken during injection to avoid leakage into the surrounding tissue.
None known.
Dosage of Glucose 5% Labesfal depends on the age, weight, clinical condition of the patient.
Fluid and acid base balance, serum Glucose 5% Labesfal, serum sodium, and other electrolytes may need to be monitored before and during administration, especially in patients with increased non-osmotic vasopressin release (syndrome of inappropriate antidiuretic hormone secretion, SIADH) and in patients co-medicated with vasopressin agonists due to the risk of hyponatraemia.
Monitoring of serum sodium is particularly important for physiologically hypotonic fluids (in vivo tonicity). Glucose 5% Labesfal 20 % may become extremely hypotonic after administration due to Glucose 5% Labesfal metabolism in the body.
Posology
Adults and the elderly
For the reversal of hypoglycaemic coma. Up to 125ml of a 20% w/v solution.
As an energy source and in carbohydrate depletion. Up to 3 Litres per day dependent on the needs of the patient.
Paediatric population
Only to be used under the supervision of a paediatrician
Method of administration
Glucose 5% Labesfal 20% must be administered by the intravenous route; it must not be administered by subcutaneous or intramuscular route. Except in the emergency treatment of severe hypoglycaemia, Glucose 5% Labesfal 20% should be administered via a central vein.
Glucose 5% Labesfal 20% is provided in a concentration that is ready for administration.
Use as directed by the physician.
Glucose 5% Labesfal 20% is provided in a concentration that is ready for administration.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
